Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abbott reports positive data from Parkinson’s drug trial

Abbott reports positive data from Parkinson’s drug trial

13th June 2011

Abbott has reported positive interim trial data from a clinical trial of levodopa-carbidopa intestinal gel (LCIG), its new treatment for Parkinson's disease.

Analysis of the ongoing 54-week phase III open-label study of the treatment revealed that patients are experiencing a decrease in "off" time and an increase in "on" time without troublesome dyskinesias after 12 weeks.

LCIG offers benefits compared to current treatments as it is delivered via a surgically-implanted tube, allowing medication to be continuously absorbed into the bloodstream via the small intestine.

The investigational treatment has already received regulatory approval in 38 countries.

Dr Eugene Sun, vice-president for global pharmaceutical clinical development at Abbott, said: "We look forward to additional data from ongoing studies and will continue our efforts to bring LCIG forward as a potential option for patients who no longer respond adequately to optimised oral treatment."

Last month, the company published positive phase III trial data from a study of Humira, showing its efficacy against rheumatoid arthritis when prescribed at an early stage.ADNFCR-8000103-ID-800576105-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.